PCIA
VRTX icon

Prime Capital Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Prime Capital Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Buy
2,898
+564
+24% +$250K 0.01% 448
2026
Q1 		$1.04M Sell
2,334
-75
-3% -$35K 0.01% 488
2025
Q4 		$1.09M Sell
2,409
-349
-13% -$150K 0.01% 474
2025
Q3 		$1.08M Sell
2,758
-238
-8% -$99.5K 0.01% 468
2025
Q2 		$1.33M Sell
2,996
-735
-20% -$339K 0.02% 415
2025
Q1 		$1.81M Buy
3,731
+750
+25% +$350K 0.02% 386
2024
Q4 		$1.2M Sell
2,981
-475
-14% -$220K 0.02% 396
2024
Q3 		$1.61M Buy
3,456
+78
+2% +$37.5K 0.02% 352
2024
Q2 		$1.58M Sell
3,378
-734
-18% -$319K 0.02% 342
2024
Q1 		$1.72M Buy
4,112
+718
+21% +$304K 0.02% 370
2023
Q4 		$1.38M Buy
3,394
+1,741
+105% +$643K 0.02% 382
2023
Q3 		$575K Sell
1,653
-993
-38% -$347K 0.01% 444
2023
Q2 		$931K Buy
2,646
+1,808
+216% +$609K 0.02% 370
2023
Q1 		$264K Buy
838
+35
+4% +$10.5K 0.01% 448
2022
Q4 		$232K Buy
+803
New +$245K 0.01% 467
2019
Q4 		– Sell
-60
Closed -$10K – 650
2019
Q3 		$10K Buy
+60
New +$10.6K ﹤0.01% 522

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Prime Capital Investment Advisors's VRTX Position: Q2 2026 in Review

Prime Capital Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 24% in Q2 2026, buying an estimated $250K and bringing the position to 2,898 shares worth $1.44M. The position accounts for 0.01% of the portfolio, ranked #448.

Prime Capital Investment Advisors first reported a position in VRTX in Q3 2019 and has held it in 16 quarters since. The position peaked at $1.81M in Q1 2025. 1,319 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Prime Capital Investment Advisors held 2,898 shares of Vertex Pharmaceuticals worth $1.44M as of Q2 2026.
  • Prime Capital Investment Advisors bought 564 Vertex Pharmaceuticals shares in Q2 2026, an estimated $250K.
  • Vertex Pharmaceuticals made up 0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #448 holding.
  • Prime Capital Investment Advisors first reported a position in Vertex Pharmaceuticals in Q3 2019 and has held it in 16 quarters since.
  • Prime Capital Investment Advisors's Vertex Pharmaceuticals position peaked at $1.81M in Q1 2025.
  • 1,319 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.